Last reviewed · How we verify
ziprasidone or olanzapine
Both ziprasidone and olanzapine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms.
Both ziprasidone and olanzapine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms. Used for Schizophrenia, Bipolar disorder (acute mania and maintenance), Agitation associated with schizophrenia or bipolar disorder.
At a glance
| Generic name | ziprasidone or olanzapine |
|---|---|
| Sponsor | Medical University of Vienna |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor; Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Ziprasidone and olanzapine work by antagonizing dopamine D2 receptors in the mesolimbic and mesocortical pathways, which reduces positive symptoms of psychosis, while also blocking serotonin 5-HT2A receptors, which may enhance antipsychotic efficacy and reduce extrapyramidal side effects. Both agents are considered atypical antipsychotics due to their combined dopaminergic and serotonergic activity, distinguishing them from first-generation antipsychotics.
Approved indications
- Schizophrenia
- Bipolar disorder (acute mania and maintenance)
- Agitation associated with schizophrenia or bipolar disorder
Common side effects
- Weight gain
- Sedation
- Metabolic syndrome (hyperglycemia, dyslipidemia)
- Akathisia
- Orthostatic hypotension
- QT prolongation (ziprasidone)
Key clinical trials
- Maternal And Infant Antipsychotic Study
- A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication (PHASE2)
- Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. (PHASE3)
- Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
- An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics
- A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ziprasidone or olanzapine CI brief — competitive landscape report
- ziprasidone or olanzapine updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI